^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    JCO Precis Oncol
    Title:

    Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes

    Published date:
    03/02/2022
    Excerpt:
    Median progression-free survival was shorter in patients with evaluated germline pathogenic variants (10.2 months [95% CI, 5.7 to 14.7])...In this retrospective real-world study, gBRCA1/2-ATM-CHEK2 pathogenic variants were independently associated with poor outcomes in patients with advanced breast cancer treated with CDK4/6 inhibitors.
    DOI:
    10.1200/PO.21.00140
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SABCS 2021
    Title:

    Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance

    Published date:
    10/09/2021
    Excerpt:
    Strikingly, gBRCA2 PVs were significantly associated with inferior PFS (HR 2.17, 95% CI 1.46-3.22, p < 0.001) on first line treatment with CDK4/6i-ET...Among these, we demonstrated BRCA2 carriers to have inferior outcomes to first line CDK4/6i-ET with potential implications for optimal first line therapy and sequencing of CDK4/6i vs PARPi in this patient population.
    Secondary therapy:
    Hormone Therapy